Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Acino Holding AG's FCF Margin % or its related term are showing as below:
LTS:0QM8's FCF Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.585 * Ranked among companies with meaningful FCF Margin % only.
Acino Holding AG FCF Margin % Related Terms
Acino Holding AG FCF Margin % Historical Data
* Premium members only.
The historical data trend for Acino Holding AG's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acino Holding AG FCF Margin % Competitor Comparison
For the Drug Manufacturers - General subindustry, Acino Holding AG's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acino Holding AG FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Acino Holding AG's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Acino Holding AG's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acino Holding AG (LTS:0QM8) has a FCF Margin % of 0.75% as of Dec. 2013. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Acino Holding AG and its competitors.
Is Acino Holding AG's FCF Margin % too high?
Acino Holding AG's current FCF Margin % is 0.75%. The Drug Manufacturers industry median FCF Margin % is 2.59. Acino Holding AG's value of 0.75% is 71% below this industry median.
How does Acino Holding AG's FCF Margin % compare to competitors?
Acino Holding AG's FCF Margin % of 0.75% can be compared against companies in the Drug Manufacturers industry. The industry median FCF Margin % is 2.59. Acino Holding AG's value of 0.75% is 71% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.59, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Acino Holding AG's current FCF Margin % of 0.75% is 71% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Acino Holding AG and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acino Holding AG's current FCF Margin % is 0.75%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acino Holding AG stock overvalued right now?
Acino Holding AG (LTS:0QM8) has a current FCF Margin % of 0.75%. The current FCF Margin % is 0.75% and 71% below the Drug Manufacturers industry median of 2.59. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Acino Holding AG (LTS:0QM8), the current FCF Margin % is 0.75% as of Dec. 2013. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Acino Holding AG is a Switzerland-based company engaged in the pharmaceutical industry. The Company develops, manufactures, and markets pharmaceuticals in novel drug delivery forms internationally. It is divided into four segments Business to Consumer (BtC); Business to Business (BtB); Technology marketing (TM); and Production (Prod). The BtC segment comprises all direct marketing activities. Under the company's "Acino Switzerland" brand and, with the promise of Swiss quality, the company sells its products in emerging markets around the globe. This reporting segment includes the business purchased from Mepha/Cephalon in the Middle East, Africa, Latin America and Asia. The BtB segment comprises Acino's business with its internally developed products, for which the company also owns the intellectual property rights. Acino develops and produces high-quality medicines with proven active ingredients and modern drug delivery systems and grants licenses for them to leading pharmaceutical and generic pharmaceutical companies worldwide. The technology marketing segment comprises a broad spectrum of fully integrated contract services, including procurement, contract development, production and packaging for companies in the life sciences industry. On behalf of these customers, Acino develops a comprehensive product pipeline on the basis of its special technological know-how. This includes both new types of medicines as well as projects with innovative drug delivery systems for established active ingredients. The production segment is responsible for the manufacturing of products and the supplying of the other three segments, and generates turnover through the reimbursement of its services. The manufacturing costs of products are credited to the production segment at standard prices along with remuneration in the form of a mark-up for materials and production costs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0QM8 has been successfully added to your 
